Clôture précédente | 105,85 |
Ouverture | 106,00 |
Offre | 104,70 x 1300 |
Vente | 0,00 x 800 |
Var. jour | 104,76 - 106,43 |
Sur 52 semaines | 79,23 - 115,49 |
Volume | |
Volume moyen | 8 805 869 |
Cap. boursière | 267,586B |
Bêta (mensuel sur 5 ans) | 0,37 |
Rapport P/E (sur 12 mois) | 38,11 |
BPA (sur 12 mois) | 2,77 |
Date de bénéfices | 27 avr. 2023 |
Dividende et rendement à terme | 2,92 (2,76 %) |
Date ex-dividende | 14 mars 2023 |
Objectif sur 1 an | 118,04 |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
Providing vaccines to some of the hardest-to-reach places around the world